drugset / Trial / NCT06773663

Application of Al18F-NOTA-Pentixafor PET/CT for Primary Aldosteronism

NCT06773663 ↗

Phase 1/2 Recruiting 150 enrolled Peking Union Medical College Hospital
NaSingle-groupOpen-labelDiagnostic

Summary

This prospective, single-center study investigates the biodistribution, dosimetry, safety, diagnostic performance of Al18F-NOTA-Pentixafor PET imaging in patients with primary aldosteronism. And evaluates the potential of Al18F-NOTA-Pentixafor PET imaging in surgical strategy guidance.

Timeline

Start
2023-12-30
Primary completion
2026-05-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Al18F-NOTA-Pentixafor Diagnostic / imaging agent 4.81 mbq/kg Intravenous